Trending menu:
News
-
17 September 2019
Cassava Sciences to assess Alzheimer’s drug in Phase IIb trial
US-based biopharmaceutical firm Cassava Sciences has started a Phase IIb clinical trial to assess PTI-125 for the treatment of Alzheimer’s disease.
-
17 September 2019
hyperCORE International collaborates with VirTrial
Independent clinical research site network hyperCORE International has collaborated with VirTrial for a training programme.
-
17 September 2019
Arrowhead reports initial data for cardiometabolic candidates
Arrowhead Pharmaceuticals has reported initial results from Phase I clinical trials of its RNAi-based cardiometabolic candidates ARO-APOC3 and ARO-ANG3 in patients with hypertriglyceridemia and dyslipidemia.
-
16 September 2019
Novartis’ Phase III studies of ofatumumab achieve primary goals
Novartis has reported positive findings from the Phase III ASCLEPIOS I and II clinical trials of ofatumumab (OMB157), which met their primary endpoints in relapsing forms of multiple sclerosis (RMS)...
-
16 September 2019
Accenture and Bayer to implement INTIENT Clinical platform
Accenture will partner with Bayer to implement the Accenture INTIENT Clinical platform for research, clinical development, pharmacovigilance and patient services.
-
16 September 2019
Eisai and Biogen end elenbecestat clinical trials in early AD
Eisai and Biogen have decided to stop Phase III clinical studies on the investigational oral beta amyloid cleaving enzyme (BACE) inhibitor elenbecestat in patients with early Alzheimer's disease (AD).
-
16 September 2019
Celgene’s Phase III study for myeloid leukaemia meets endpoints
Celgene has announced that the Phase III QUAZAR AML-001 clinical trial of CC-486 as maintenance therapy for acute myeloid leukaemia (AML) met primary and key secondary endpoints.
-
13 September 2019
Study finds Janssen’s ponesimod superior to Sanofi’s Aubagio
Johnson & Johnson unit Janssen Pharmaceutical has reported positive data from the Phase III OPTIMUM trial, where its ponesimod demonstrated superior efficacy compared to Sanofi’s Aubagio (teriflunomide) in relapsing multiple...
-
13 September 2019
Signant Health to assist Shanghai Mental Health Center in trial
Shanghai Mental Health Center (SMHC) has selected Signant Health to provide electronic informed consent for a neuroscience study on schizophrenia.
-
13 September 2019
Tocagen’s cancer drug fails to improve survival in glioma trial
A Phase III clinical trial performed by Tocagen to assess its cancer immunotherapy, Toca 511 & Toca FC, has failed to meet the primary endpoint of overall survival in patients...